HKBU recently received a generous donation of HK$900,000 from Qingfeng Pharmaceutical Group to support the development of novel drugs based on Chinese medicine. In addition, The Group commissioned the University’s School of Chinese Medicine to carry out a five-year research project entitled “Aptamer modified Paclitaxel for tumor treatment” and committed HK$2.7 million for the study. In recognition of the donor’s generosity, the University held an agreement signing-cum-cheque presentation ceremony today (4 September). Attending the ceremony were Mr. Tang Chunshan, Managing Director of Qingfeng Pharmaceutical Group, Professor Albert Chan, President and Vice-Chancellor of HKBU, Professor Rick Wong, Vice-President (Research and Development), and Professor Lu Aiping, Dean of the School of Chinese Medicine.
At the ceremony, Professor Albert Chan said that collaboration between academia and industry is a perfect match, creating a win-win outcome. The School and The Group shared common goals for human health and well-being, and achieve those goals through the deployment of quality research teams that merge Chinese medicine with modern technology in the search for new drugs. Professor Chan hopes that the research project will produce groundbreaking outcomes in the discovery of new drugs for treating cancer.
Professor Albert Chan (fourth from left) receives the cheque from Mr. Tang Chunshan (centre) at the ceremony.